Jobb & karriär
Koncern nyheter
10-maj-2012
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care"
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care"
27-apr-2012
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1
26-apr-2012
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed
20-apr-2012
First approval worldwide for EverGol™ in seed treatment
Launch in Canada planned before the end of the year
First approval worldwide for EverGol™ in seed treatment
Launch in Canada planned before the end of the year
12-apr-2012
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE (for specialized target groups only)
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE (for specialized target groups only)
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE
14-mar-2012
Bayer sets ambitious targets for 2014
Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position
Bayer sets ambitious targets for 2014
Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position
Sök
Avancerad sökning 
Snabblänkar
Bayer Share Price